Strategic Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
FP
TP
Strategic Advisors's MRNA Position: Q1 2022 in Review
Strategic Advisors sold out of Moderna (MRNA) in Q1 2022, closing a stake of 24,436 shares — an estimated $6.21M sold.
Strategic Advisors first reported a position in MRNA in Q4 2020 and held it in 5 quarters. The position peaked at $9.96M in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.
- Strategic Advisors reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
- Strategic Advisors sold 24,436 Moderna shares in Q1 2022, an estimated $6.21M.
- Strategic Advisors first reported a position in Moderna in Q4 2020 and held it in 5 quarters.
- Strategic Advisors's Moderna position peaked at $9.96M in Q3 2021.
- 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.
Based on Strategic Advisors's 13F filing for Q1 2022, filed 10 May 2022.